FI891226A0 - Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. - Google Patents

Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.

Info

Publication number
FI891226A0
FI891226A0 FI891226A FI891226A FI891226A0 FI 891226 A0 FI891226 A0 FI 891226A0 FI 891226 A FI891226 A FI 891226A FI 891226 A FI891226 A FI 891226A FI 891226 A0 FI891226 A0 FI 891226A0
Authority
FI
Finland
Prior art keywords
reseptordeterminanter
autoimmunsjukdom
celler
foer behandling
behandling
Prior art date
Application number
FI891226A
Other languages
English (en)
Other versions
FI891226A (fi
Inventor
Lawrence Steinman
Scott S Zamvil
Dennis J Mitchell
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22692581&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI891226(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of FI891226A0 publication Critical patent/FI891226A0/fi
Publication of FI891226A publication Critical patent/FI891226A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
FI891226A 1988-04-28 1989-03-15 Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. FI891226A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18829788A 1988-04-28 1988-04-28

Publications (2)

Publication Number Publication Date
FI891226A0 true FI891226A0 (fi) 1989-03-15
FI891226A FI891226A (fi) 1989-10-29

Family

ID=22692581

Family Applications (1)

Application Number Title Priority Date Filing Date
FI891226A FI891226A (fi) 1988-04-28 1989-03-15 Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.

Country Status (12)

Country Link
EP (1) EP0340109B1 (fi)
JP (2) JPH0272197A (fi)
AT (1) ATE153704T1 (fi)
AU (1) AU635202B2 (fi)
DE (1) DE68928069T2 (fi)
DK (1) DK203489A (fi)
ES (1) ES2104565T3 (fi)
FI (1) FI891226A (fi)
GR (1) GR3024532T3 (fi)
HK (1) HK1005597A1 (fi)
IL (1) IL89865A (fi)
NO (1) NO891705L (fi)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2621127B1 (fr) * 1987-09-30 1992-01-31 Roussy Inst Gustave Anticorps monoclonal reconnaissant un epitope de la chaine gamma des recepteurs de surface des cellules t humaines, lignee de cellules d'hybridomes produisant cet anticorps, et utilisation de cet anticorps monoclonal
DE3828582A1 (de) * 1988-08-23 1990-03-01 Max Planck Gesellschaft Monoklonaler antikoerper zur inhibierung der infektion von zellen durch hiv-viren
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US6221352B1 (en) 1989-03-21 2001-04-24 The Immune Response Corporation Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
RO110397B1 (ro) * 1989-03-21 1996-01-30 Immune Response Corp San Diego Vaccin pentru prevenirea sau tratarea unor boli care rezulta din raspunsuri patogene, prin populatii de celule t specifice, procedeu de obtinere si metode de diagnostic si tratament cu acesta
US6207645B1 (en) * 1989-03-21 2001-03-27 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US5837246A (en) * 1989-03-21 1998-11-17 The Immune Response Corporation Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
US6113903A (en) * 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
CA2064077C (en) * 1989-07-19 2002-03-12 Arthur A. Vandenbark T cell receptor peptides as therapeutics for autoimmune and malignant disease
US5776459A (en) * 1989-07-19 1998-07-07 Connetics Corporation TCR V beta 5 peptides
US5547669A (en) * 1989-11-03 1996-08-20 Immulogic Pharma Corp Recombinant peptides comprising T cell epitopes of the cat allergen, Fel d I
CA2068888A1 (en) * 1989-11-15 1991-05-16 Brian L. Kotzin Method for measuring t-cell surface antigens in humans
JPH05506995A (ja) * 1990-05-01 1993-10-14 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 疾患関連マーカーとしてのｔ細胞レセプター可変トランスクリプト
CA2065658A1 (en) * 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
US5445940A (en) * 1991-08-28 1995-08-29 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease
US5747036A (en) * 1991-08-28 1998-05-05 Brigham & Women's Hospital Methods and compositions for detecting and treating a subset of human patients having an autoimmune disease
WO1993004695A1 (en) * 1991-08-28 1993-03-18 The Wistar Institute T cell receptor-based therapy for rheumatoid arthritis
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
CA2144044A1 (en) * 1992-09-14 1994-03-31 The Brigham And Women's Hospital Reagents and methods for treating rheumatoid arthritis
CA2904259C (en) 1999-05-07 2016-11-15 Genentech, Inc. Use of rituximab to treat vasculitis
EP2052742A1 (en) 2000-06-20 2009-04-29 Biogen Idec Inc. Treatment of B-cell associated diseases such as malignancies and autoimmune diseases using a cold anti-CD20 antibody/radiolabeled anti-CD22 antibody combination
US20020159996A1 (en) 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
WO2002060484A1 (en) 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Use of cd23 antagonists for the treatment of neoplastic disorders
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
JP4351674B2 (ja) 2002-12-16 2009-10-28 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体とその使用法およびその使用
AU2004229376B2 (en) 2003-04-09 2007-12-13 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor
CN102512675A (zh) 2004-06-04 2012-06-27 健泰科生物技术公司 用于治疗多发性硬化的方法
EP1853718B1 (en) 2005-02-15 2015-08-05 Duke University Anti-cd19 antibodies and uses in oncology
RU2007137489A (ru) 2005-03-10 2009-04-20 Дженентек, Инк. (Us) Способы и композиции для модуляции целостности сосудов
CA2607281C (en) 2005-05-05 2023-10-03 Duke University Anti-cd19 antibody therapy for autoimmune disease
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2737907A3 (en) 2007-05-07 2014-11-05 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
EP2397154B1 (en) 2007-08-15 2015-07-15 Circassia Limited Peptides for desensibilization against allergens
EP3808348A1 (en) 2007-09-14 2021-04-21 Biogen MA Inc. Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (pml)
JP5490714B2 (ja) 2007-11-28 2014-05-14 メディミューン，エルエルシー タンパク質製剤
US20100255508A1 (en) 2008-05-16 2010-10-07 Thomas Richard Gelzleichter Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
US20100105620A1 (en) 2008-10-10 2010-04-29 Anaphore, Inc. Polypeptides that bind Trail-R1 and Trail-R2
CA2743469C (en) 2008-11-12 2019-01-15 Medimmune, Llc Antibody formulation
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2011014750A1 (en) 2009-07-31 2011-02-03 Genentech, Inc. Inhibition of tumor metastasis using bv8- or g-csf-antagonists
RU2573915C2 (ru) 2009-09-16 2016-01-27 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применение
CA2772670A1 (en) 2009-09-17 2011-03-24 F. Hoffmann-La Roche Ag Methods and compositions for diagnostics use in cancer patients
WO2011060015A1 (en) 2009-11-11 2011-05-19 Genentech, Inc. Methods and compositions for detecting target proteins
BR112012012983A2 (pt) 2009-12-04 2020-09-15 Genentech Inc método para sintetizar um anticorpo multiespecífico, método para sintetizar um painel de anticorpos multiespecíficos, método para sintetizar um análogo de anticorpo, método para sintetizar um painel de análogos de anticorpo e composições
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CN105001330B (zh) 2010-04-23 2020-05-01 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
EP2609111B1 (en) 2010-08-24 2017-11-01 F. Hoffmann-La Roche AG Bispecific antibodies comprising a disulfide stabilized-fv fragment
KR20190120439A (ko) 2010-11-08 2019-10-23 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
WO2012085111A1 (en) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
AR085138A1 (es) 2011-02-04 2013-09-11 Genentech Inc VARIANTES DE Fc Y METODOS PARA SU PRODUCCION
CN114642731A (zh) 2011-03-31 2022-06-21 豪夫迈·罗氏有限公司 施用β7整联蛋白拮抗剂的方法
SG195170A1 (en) 2011-07-04 2013-12-30 Mesoblast Inc Methods of treating or preventing rheumatic disease
WO2013013708A1 (en) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Treatment of acute rejection in renal transplant
CN103890008A (zh) 2011-08-17 2014-06-25 霍夫曼-拉罗奇有限公司 在顽固性肿瘤中抑制血管发生
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
BR112014018471A2 (pt) 2012-01-31 2017-07-04 Genentech Inc anticorpos anti-ige m1' e métodos para o seu uso
BR112014019579A2 (pt) 2012-02-10 2019-10-15 Genentech, Inc Anticorpo de cadeia única, polinucleotídeo, vetor, célula hospedeira, método de produção de um anticorpo de cadeia única, heteromultímero e método de produção do heteromultímero
ES2652136T3 (es) 2012-02-16 2018-01-31 Atyr Pharma, Inc. Histidil-tRNA sintetasas para tratar enfermedades autoinmunitarias e inflamatorias
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
EP2867254B1 (en) 2012-06-27 2017-10-25 F. Hoffmann-La Roche AG Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
CN104870056A (zh) 2012-10-05 2015-08-26 弗·哈夫曼-拉罗切有限公司 用于诊断和治疗炎性肠病的方法
EP2959014B1 (en) 2013-02-25 2019-11-13 Genentech, Inc. Methods and compositions for detecting and treating drug resistant akt mutant
WO2014151517A1 (en) 2013-03-15 2014-09-25 Intermune, Inc. Methods of improving microvascular integrity
SG11201507974RA (en) 2013-03-27 2015-10-29 Genentech Inc Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
SG11201607938UA (en) 2014-03-27 2016-10-28 Genentech Inc Methods for diagnosing and treating inflammatory bowel disease
BR112016024462B1 (pt) 2014-05-06 2022-12-27 Genentech, Inc Métodos para a preparação de um anticorpo
WO2016040868A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anti-cll-1 antibodies and immunoconjugates
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
US9975949B2 (en) 2014-12-05 2018-05-22 Genentech, Inc. Anti-CD79b antibodies and methods of use
EP3978530A1 (en) 2015-02-26 2022-04-06 F. Hoffmann-La Roche AG Integrin beta7 antagonists and methods of treating crohn's disease
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
RS62986B1 (sr) 2015-06-24 2022-03-31 Hoffmann La Roche Antitela na transferinski receptor sa prilagođenim afinitetom
AU2016285596A1 (en) 2015-06-29 2018-01-18 Genentech, Inc. Type II anti-CD20 antibody for use in organ transplantation
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TWI819458B (zh) 2015-10-02 2023-10-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
MA43345A (fr) 2015-10-02 2018-08-08 Hoffmann La Roche Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
IL293708A (en) 2015-10-06 2022-08-01 Genentech Inc A method for treating multiple sclerosis
EP3397287A1 (en) 2015-12-30 2018-11-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
WO2017201449A1 (en) 2016-05-20 2017-11-23 Genentech, Inc. Protac antibody conjugates and methods of use
WO2018106931A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112264A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
MX2019006821A (es) 2016-12-14 2019-10-21 Progenity Inc Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de cinasa de janus (jak) y dispositivos.
EP3554345A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
EP3554342A1 (en) 2016-12-14 2019-10-23 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
US11597762B2 (en) 2016-12-14 2023-03-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an IL-12/IL-23 inhibitor released using an ingestible device
CA3046019A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
WO2018112255A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
EP3601531B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with live biotherapeutics
US11596670B2 (en) 2017-03-30 2023-03-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
WO2018183934A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
CN111601597B (zh) 2017-08-23 2023-10-13 科智生命科学公司 自身免疫性病症的治疗中的免疫蛋白酶体抑制剂和免疫抑制剂
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
RU2724469C2 (ru) 2018-10-31 2020-06-23 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с cd20
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US20220364171A1 (en) 2018-11-23 2022-11-17 Katholieke Universiteit Leuven Predicting a treatment response in inflammatory bowel disease
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
EP3870261B1 (en) 2019-12-13 2024-01-31 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2023086910A1 (en) 2021-11-12 2023-05-19 Genentech, Inc. Methods of treating crohn's disease using integrin beta7 antagonists

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
US4886743A (en) * 1985-04-24 1989-12-12 California Institute Of Technology Diagnostic reagents based on unique sequences within the variable region of the T cell receptor and uses thereof
DE3650184T2 (de) * 1985-12-03 1995-05-11 T Cell Sciences Inc Zellenfreier t-zellenantigenrezeptor und klinische verwendung.
US5340921A (en) * 1986-07-03 1994-08-23 T Cell Sciences, Inc. Γ, δT cell receptor and methods and detection

Also Published As

Publication number Publication date
DK203489D0 (da) 1989-04-27
NO891705D0 (no) 1989-04-25
DE68928069T2 (de) 1997-11-13
AU635202B2 (en) 1993-03-18
DE68928069D1 (de) 1997-07-03
JPH0272197A (ja) 1990-03-12
NO891705L (no) 1989-10-30
JPH11196871A (ja) 1999-07-27
IL89865A (en) 1994-12-29
HK1005597A1 (en) 1999-01-15
FI891226A (fi) 1989-10-29
DK203489A (da) 1989-10-29
AU3322089A (en) 1989-11-02
EP0340109A3 (en) 1991-10-23
ATE153704T1 (de) 1997-06-15
IL89865A0 (en) 1989-12-15
GR3024532T3 (en) 1997-12-31
EP0340109B1 (en) 1997-05-28
ES2104565T3 (es) 1997-10-16
EP0340109A2 (en) 1989-11-02

Similar Documents

Publication Publication Date Title
FI891226A0 (fi) Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom.
Carayannopoulos et al. Ligands for murine NKG2D display heterogeneous binding behavior
Janeway Jr et al. Efficiency of antigen presentation differs in mice differing at the Mls locus
Kao et al. A peptide derived from the amino terminus of endothelial-monocyte-activating polypeptide II modulates mononuclear and polymorphonuclear leukocyte functions, defines an apparently novel cellular interaction site, and induces an acute inflammatory response
IL138424A (en) Covalently reactive antigen analogs and pharmaceutical compositions containing the same
DK0751992T3 (da) Karendotelvækstfaktor 2
AU2349697A (en) Monoclonal antibodies against the interferon receptor with neutralizing activity against type I interferon
WO1989004875A3 (en) Characterization and detection of sequences associated with autoimmune diseases
DK0669979T3 (da) C-C CKR-1, kemokinreceptor
Zuo et al. The biological influence and clinical relevance of polymorphism within the NKG2D ligands
KR980002066A (ko) 변이형 인간 성장호르몬 및 그의 용도
Rohren et al. Peptide-induced conformational changes in class I molecules. Direct detection by flow cytometry.
Jin et al. A fraction of CD3 epsilon subunits exists as disulfide-linked dimers in both human and murine T lymphocytes.
DE3855634D1 (de) Innerhalb des alpha-Locus gelegenes T-Zell-Rezeptor-Gen und DNA-Konstruktionen
Kirchner Interferon gamma
AU3047595A (en) Methods for detecting glucagon antagonists
ATE283703T1 (de) Neurodegenerative-erkrankung verwandtes gen
DE3850933D1 (de) Anticoagulatorisches Protein PP4-X, seine Herstellung und Verwendung.
TW429262B (en) C5a receptor antagonists having substantially no agonist activity
Noviello et al. Immunomodulatory responses to δ-opioid receptor ligands in human lymphocytes
ATE260339T1 (de) Antikörper gegen menschliches restrictin
Shan et al. Reverse‐phase high‐performance liquid chromatography of nerve growth factor receptor‐like proteins identified with monoclonal antibodies
Hayakawa et al. Alloantibody to a sex-influenced esterase in rats (Rattus norvegicus)
Hide et al. IgE receptor autoantibodies
Kishimoto et al. Regulation of Human B Cell Differentiation: Molecular Structure and Immunological Functions of Human B Cell Differentiation Factor (BSF-2)

Legal Events

Date Code Title Description
FD Application lapsed
MM Patent lapsed

Owner name: THE BOARD OF TRUSTEES OF THE LELAND